Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,660 across all filing types
Latest filing 2024-11-11 Capital/Financing Update
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Monitoring Agency Report
Capital/Financing Update Classification · 95% confidence The document is titled 'Monitoring Agency Report for the quarter ended 30th September 2024' and is issued pursuant to SEBI regulations related to the monitoring of proceeds from a Qualified Institutions Placement (QIP). It is a detailed report by CARE Ratings Limited, the appointed Monitoring Agency, assessing the utilization of funds raised through the QIP. The report includes financial details, certifications, and comments on the use of proceeds, consistent with regulatory requirements for monitoring capital raised through equity issuance. This is not a general financial report like an Annual Report or Interim Report, nor is it an announcement or certification only. It is a specialized monitoring report related to capital raising and fund utilization, which fits best under the category of Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content confirm it is the report itself, not just an announcement.
2024-11-11 English
Please find enclosed monitoring agency report issued by Care Ratings Ltd., being a monitoring agency, appointed for the QIP issue of the company.
Capital/Financing Update Classification · 95% confidence The document is titled 'Monitoring Agency Report for the quarter ended 30th September 2024' and is issued pursuant to SEBI regulations related to the monitoring of proceeds from a Qualified Institutions Placement (QIP). It is a detailed report by CARE Ratings Limited, the appointed Monitoring Agency, assessing the utilization of funds raised through the QIP. The report includes specific financial details about the issue proceeds, their utilization, and compliance with the offer document. The document is about monitoring the use of capital raised and is not a general financial report like an annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory compliance report specific to capital raising and fund utilization monitoring. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2024-11-11 English
Please find attached statement of Deviation & Variation for the quarter ended September 30, 2024.
Regulatory Filings
2024-11-11 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release announcing Morepen Laboratories' financial results for Q2 FY25, highlighting a 64% jump in net profit and other financial metrics. It includes detailed financial highlights, growth strategies, and business segment updates. The document is dated November 11, 2024, and is addressed to stock exchanges for dissemination. It is not a full financial report but an initial announcement of quarterly financial results with key highlights. Therefore, it fits the definition of an Earnings Release (ER). The document length (9137 characters) supports it being a detailed press release rather than a brief announcement or a full annual/interim report. Q2 2025
2024-11-11 English
General Updates
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation (Q2’ FY25) November 2024' and is addressed to stock exchanges with a subject line explicitly stating it is an investor presentation. The content includes forward-looking statements, financial highlights for the quarter and half year ended 30th September 2024, and business strategy information. It is a detailed presentation prepared for investors, containing financial performance data and strategic outlook. There is no indication that this is a full annual or interim report, audit report, earnings release, or regulatory filing. The document is not a brief factsheet or a voting result announcement. It is clearly an investor presentation as per the description and content. The document length is substantial (15,000 characters), indicating it is the presentation itself, not just an announcement of it. Therefore, the correct classification is Investor Presentation (IP).
2024-11-11 English
Please find attached press release.
Earnings Release Classification · 95% confidence The document is a press release announcing Morepen Laboratories' financial results for Q2 FY25, highlighting a 64% jump in net profit and other financial metrics. It includes financial highlights, strategic plans, and quotes from the Chairman and Managing Director. The document is dated November 11, 2024, and is addressed to stock exchanges for dissemination. It is not a full financial report but a summary announcement of quarterly financial performance. The length is 9137 characters, which is consistent with a press release rather than a full interim or annual report. Therefore, this document fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only. Q2 2025
2024-11-11 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.